Overseas income has been declining year after year, zhejiang orient gene biotech sets up a new subsidiary to seek the Southeast Asian market.

①Zhejiang Orient Gene Biotech expands its wholesale trade business of medical instruments by establishing a new company in the Philippines, and expands its market in Southeast Asia and South Asia. ②Currently, Zhejiang Orient Gene Biotech's key overseas markets are mainly in the Americas and Europe, but in recent years, the revenue from overseas markets has been rapidly declining.

cls.cnSep 12 15:07

Livzon Pharmaceutical Group Inc. expects reduced performance pressure in the second half of the year | Live coverage of the earnings conference

At the earnings conference, Yang Liang, the secretary of Livzon Pharmaceutical Group Inc., responded to issues such as the year-on-year decrease in company revenue and financial data of various sector businesses. The company's CEO, Tang Yanggang, stated that the overall market size of Tocilizumab Injection is not large in China.

cls.cnSep 10 19:50

Another unreasonable suppression! The U.S. House of Representatives has passed the Biosecurity Act, and wuxi apptec and wuxi bio have quickly responded.

①The U.S. House of Representatives passed the draft of the Biosecurity Act (H.R.8333) with 306 votes in favor and 81 votes against. ②Wuxi Apptec, Wuxi Bio, and other companies strongly opposed it. ③This bill still needs to be voted on by the Senate and the versions passed by both houses need to be reconciled before it can be submitted to the U.S. President for signing into law.

cls.cnSep 10 10:48

Next week, the scale of A-share unlocking will nearly double! Citic Securities leads the way, with over 17 billion yuan being unlocked.

Peak of lifting the ban within the month! The scale of lifting the ban next week will nearly double compared to the previous period; After a six-month delay, the "top brokerage" will lift the ban of over 17 billion next week; 5 individual stocks with large amounts and high proportions will be lifted off the list simultaneously.

cls.cnSep 8 11:40

Ruiang's net income in the first half of the year dropped by over 40%. The senior management is suspected of illegal operation and is still under investigation for evidence collection.

①Due to the increase in credit impairment losses of accounts receivable and the increase in marketing expenses in sales expenses, Ruiang Gene's net income in the first half of the year fell by 43.20% to 9.2218 million yuan; ②Regarding the alleged illegal operation of multiple senior executives, Ruiang Gene revealed that the relevant evidence collection work is in progress, and the matter is still under further investigation.

cls.cnAug 29 20:27

The decline in the pharmaceutical sector is affecting overall revenue. Fosun Pharma: Will focus on building super 1 billion yuan big varieties | Earnings conference highlights.

Fosun Pharma's revenue from innovative drugs in the first half of the year exceeded 3.7 billion yuan, accounting for about 18% of the overall revenue. Wu Yifang revealed that the business of innovative drugs will strive to achieve a compound annual growth rate of 30% in the next few years. Wu Yifang said that the privatization of Henlius is currently underway, and the entire business and pipeline of Henlius will be deeply integrated with Fosun Pharma through privatization.

cls.cnAug 29 07:29